Thomas Spitznagel
Corporate Officer/Principal chez MACROGENICS, INC.
Fortune : 34 012 $ au 31/05/2024
Profil
Thomas M.
Spitznagel is currently the Senior Vice President-Technical Operations at MacroGenics, Inc. Prior to his current position, he held the role of Vice President-BioPharmaceutical Development at Human Genome Sciences, Inc. from 1998 to 2012.
He also worked as a Staff Engineer at Genetics Institute LLC from 1992 to 1996 and as a Senior Scientist at Nabi Biopharmaceuticals from 1996 to 1998.
Dr. Spitznagel obtained his undergraduate degree from the Massachusetts Institute of Technology and his doctorate degree from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MACROGENICS, INC.
0,01% | 04/03/2024 | 8 316 ( 0,01% ) | 34 012 $ | 31/05/2024 |
Postes actifs de Thomas Spitznagel
| Sociétés | Poste | Début |
|---|---|---|
| MACROGENICS, INC. | Corporate Officer/Principal | 01/01/2013 |
Anciens postes connus de Thomas Spitznagel
| Sociétés | Poste | Fin |
|---|---|---|
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/07/2012 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Directeur Technique/Scientifique/R&D | 01/01/1998 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1996 |
Formation de Thomas Spitznagel
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
